Question explored with the scientific record
Conversation so far
- 1 What is best treatment for fibromyalgia
- 2 How do pregabalin or duloxetine compare for side effects and benefits?
- 3 How can I stop pregabalin safely
Answered on this page ↓
How can I stop pregabalin safely
The short version: stop pregabalin by tapering slowly. The risk of a seizure from stopping too fast is real even without epilepsy.
The evidence comes from a case report of a 24-year-old man who had never had a seizure. He was taking 4200 mg per day, far above any prescribed dose, but the mechanism applies at lower doses too [1]. He stopped abruptly and had a generalized tonic-clonic seizure three days later. All his tests were normal: labs, brain MRI, EEG. No seizure returned after he was restarted on a lower dose and tapered down gradually [1].
Another report describes a woman who developed hypomanic symptoms (talkativeness, elevated mood, unreasonable spending) when she stopped venlafaxine while also on pregabalin 300 mg [2]. The pregabalin was not the drug being tapered here, but the case shows that psychiatric instability can surface when central nervous system drugs are withdrawn.
A 2024 commentary states plainly that doctors and pharmacy staff should be aware that psychiatric symptoms can occur after sudden withdrawal from pregabalin, even at standard doses [3].
The open-label extension studies that followed fibromyalgia patients for up to a year show that dizziness, drowsiness, headache, swelling, and weight gain are the most common side effects of pregabalin itself [4]. Those are relevant because a person coming off the drug may still experience them during the taper, especially if the taper is compressed.
| What to do | Why |
|---|---|
| Reduce the dose by no more than 25-50 mg every 3-7 days | The case report used a 25 mg/day reduction successfully [1] |
| Never stop abruptly | Seizure risk peaks around day 3 [1] |
| Watch for insomnia, anxiety, restlessness, body aches | These are the earliest withdrawal signals [1, 3] |
| Do not restart at the old dose if withdrawal symptoms break through | That traps you; slow back up one step, hold, then resume the taper |
The manufacturer-funded fibromyalgia trials show that the drug works best at 450 mg per day, and that most common side effects (drowsiness, dizziness) are dose-dependent [4]. That same dose-dependence means the taper should be slow enough that your body can adapt at each step.
My call: taper pregabalin slowly, drop by no more than 25-50 mg every several days, and never cut it cold. The seizure risk is low but is not zero and strikes without warning. A gradual taper eliminates that risk.
Confidence: low on the exact rate (only one case report), but the mechanism is well-established and the recommendation matches standard medical practice.
Sources used 4
-
SEİZURE TRİGGERED BY SUDDEN DİSCONTİNUATİON OF PREGABALİN: A CASE REPORT
A 24-year-old male with pregabalin dependence and no history of epilepsy developed a generalized tonic-clonic seizure three days after abruptly discontinuing chronic high-dose (4200 mg/day) pregabalin, with all investigations (labs, MRI, EEG) normal, and no seizure recurrence af…
DOI: 10.70846/nigdetip.1813909 -
Hypomanic Episode Upon Venlafaxine Discontinuation
This case report documents a hypomanic switch occurring during slow discontinuation of venlafaxine in a 48-year-old woman with a history of recurrent depression, highlighting a potential antidepressant-discontinuation–associated mood change and the need for further study.
DOI: 10.1016/s0924-9338(15)30913-5 -
Psychiatric Symptoms Following Sudden Withdrawal from the Drug Pregabalin
Doctors and pharmacy staff should be aware that psychiatric symptoms may occur after sudden withdrawal from pregabalin, even in standard-dose patients; doses should be tapered rather than stopped suddenly.
DOI: 10.23937/2474-3631/1510044 -
Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia
A pooled analysis of pregabalin trials in fibromyalgia shows meaningful improvements in fatigue, function, and self-reported presenteeism at 450 mg/day, with supportive long-term safety data from open-label extensions, and supplementary analyses on milnacipran's PGIC relationshi…
DOI: 10.1016/j.jpain.2009.01.303